- Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax2022 | First Faculty of Medicine
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study +12009 | Publication without faculty affiliation
- Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms2016 | Publication without faculty affiliation
- MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia2018 | Publication without faculty affiliation
- Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders2017 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS2019 | First Faculty of Medicine
- G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial2022 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Treatment strategies for myelodysplastic syndrome in 20212021 | Faculty of Medicine in Hradec Králové
- Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34(+) Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients2021 | First Faculty of Medicine
- New therapeutic approaches and perspectives in the treatment of myelodysplastic syndrome2019 | First Faculty of Medicine
- Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes2018 | Publication without faculty affiliation
- Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial2021 | Second Faculty of Medicine
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Zpráva z posledních analýz terapie Vidazou (azacitidin) a Revlimidem (lenalidomid) nemocných s myelodysplastickým syndromem v ČR - data z MyDyS registru2019 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy2022 | Central Library of Charles University
- Research Report University Hospital clinical trial AZA-MDS-003Publication without faculty affiliation
- Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes2022 | Central Library of Charles University
- Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patientsPublication without faculty affiliation
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | First Faculty of Medicine
- Sweet Syndrome in a Patient with Myelodysplastic Syndrome - Case Report2017 | First Faculty of Medicine
- Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia2015 | Second Faculty of Medicine
- 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity2012 | First Faculty of Medicine
- Patofyziologické aspekty myelodysplastického syndromu ve vztahu k efektu cílené imunomodulační a demetylační terapiePublication without faculty affiliation
- Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial2023 | Third Faculty of Medicine
- Azacytidine in tumor cells affects genes with antitumor activity2014 | First Faculty of Medicine
- Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome2020 | First Faculty of Medicine, Faculty of Science, Central Library of Charles University
- Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML2021 | First Faculty of Medicine
